Compare MMED & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMED | PTCT |
|---|---|---|
| Founded | 1983 | 1998 |
| Country | United States | United States |
| Employees | 2800 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.7B |
| IPO Year | 2025 | 2006 |
| Metric | MMED | PTCT |
|---|---|---|
| Price | $22.25 | $70.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 17 |
| Target Price | $22.56 | ★ $80.65 |
| AVG Volume (30 Days) | ★ 1.2M | 850.7K |
| Earning Date | 06-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | N/A | ★ 0.90 |
| Revenue | ★ $3,102,000,000.00 | $264,734,000.00 |
| Revenue This Year | $15.99 | N/A |
| Revenue Next Year | $10.00 | $17.70 |
| P/E Ratio | ★ N/A | $77.27 |
| Revenue Growth | 14.25 | ★ 36.19 |
| 52 Week Low | $10.65 | $52.43 |
| 52 Week High | $20.88 | $90.87 |
| Indicator | MMED | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 72.86 | 42.70 |
| Support Level | $10.68 | $69.81 |
| Resistance Level | N/A | $73.86 |
| Average True Range (ATR) | 1.04 | 1.93 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 98.20 | 38.85 |
While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.